Biotech | April 06, 2022
Aizon partners with TetraScience to help pharma companies speed up drug manufacturing efficiently
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The new facility is scheduled to start operation in the first half of 2024
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Pilots to be launched across multiple locations in India.
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Subscribe To Our Newsletter & Stay Updated
